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CONCLUSION:
Mechanisms of target organ damage are unclear 
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Abstract 
The endothelin system may be an important player in hypertensive end-organ injury as 
endothelin-1 increases blood pressure and is pro-inflammatory. The immune system is 
emerging as an important regulator of blood pressure and we have shown that the early 
hypertensive response to angiotensin-II infusion was amplified in mice deficient of myeloid 
endothelin-B (ETB) receptors (LysM-CreEdnrblox/lox). Hypothesizing that these mice would 
display enhanced organ injury, we gave angiotensin-II to LysM-CreEdnrblox/lox and 
littermate controls (Ednrblox/lox) for six weeks. Unexpectedly, LysM-CreEdnrblox/lox mice 
were significantly protected from organ injury, with less proteinuria, glomerulosclerosis and 
inflammation of the kidney compared to controls. In the eye, LysM-CreEdnrblox/lox mice 
had fewer retinal hemorrhages, less microglial activation and less vessel rarefaction. Cardiac 
remodeling and dysfunction were similar in both groups at week six but LysM-
CreEdnrblox/lox mice had better endothelial function. Although blood pressure was initially 
higher in LysM-CreEdnrblox/lox mice, this was not sustained. A natriuretic switch at about 
two weeks, due to enhanced ETB signaling in the kidney, induced a hypertensive reversal. By 
week six, blood pressure was lower in LysM-CreEdnrblox/lox mice than in controls. At six 
weeks, macrophages from LysM-CreEdnrblox/lox mice were more anti-inflammatory and 
had greater phagocytic ability compared to the macrophages of Ednrblox/lox mice. Thus, 
myeloid cell ETB receptor signaling drives this injury both through amplifying hypertension 
and by inflammatory polarization of macrophages. 
 
Key words: hypertension; organ injury; macrophages, endothelin 
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Translational statement 
Hypertension is the single largest contributor to the global burden of disease and to global 
mortality. It is a major risk factor for chronic kidney disease, atherosclerosis and retinopathy,  
end-organ effects with devastating consequences. Preventing this injury is the principal 
therapeutic goal in patients with hypertension. Our data provide novel insights into the roles 
the immune and endothelin systems in the hypertensive end-organ injury seen in the kidney, 
eye and vasculature, providing a rational basis for further investigation into the modulation of 
these pathways for therapeutic gain. These and other successful studies may encourage 
industry to take a lead in this relatively orphan area, potentially resulting in a more rational 
prescribing of endothelin receptor antagonists for hypertension. 
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Introduction  
Hypertension is the biggest single contributor to the global burden of disease and to global 
mortality.1 Currently, it is estimated that a quarter of the world’s adult population is 
hypertensive, projected to reach ~30% by 2025.2 Arterial hypertension is a major risk factor 
for atherosclerosis, coronary artery disease, stroke, and chronic kidney disease which 
underpin its devastating effects.3 Thus, preventing end-organ damage is the principal 
therapeutic goal in patients with hypertension. The last few decades have seen few advances 
in the treatment of hypertension and its complications. Improved understanding of the 
mechanisms underlying hypertensive end-organ damage might provide new therapeutic 
opportunities, particularly for those resistant to conventional blood pressure (BP)-lowering 
strategies.  
 
In this context, animal models provide an important discovery platform.4 Chronic angiotensin 
II (ANG II) infusion is widely used to capture the cardinal features of clinical disease4,5 and 
studies extending the model beyond four weeks demonstrate stable hypertension and 
significant cardiac, renal and vascular injury.4 Earlier work shows that these are blunted by 
endothelin-1 (ET-1) receptor antagonism.6,7 Indeed, ET receptor antagonism is an emerging 
therapeutic option in a number of clinical conditions including chronic kidney disease8 and 
resistant hypertension.9 This partly reflects a hemodynamic benefit since ET-1 exerts 
powerful, sustained vasoconstriction10 via activation of endothelin-A (ETA) receptors present 
on vascular smooth muscle. In addition, ETA receptor activation is directly pro-inflammatory 
and pro-fibrotic so BP-independent benefits of ET-1 antagonism may also be therapeutically 
important.  
 
There has been less focus given to the role of the endothelin-B (ETB) receptor, which exerts a 
countervailing influence on BP. Endothelial ETB activation causes vasodilation and activation 
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of ETB in the distal renal tubule promotes natriuresis.11 Additionally, the ETB receptor plays a 
key role in clearing ET-1 from the circulation and curtailing its bioactivity.12 Indeed, we 
recently showed that ETB receptor-mediated clearance of ET-1 by myeloid cells protected 
against the early development of experimental hypertension.13 Other studies also point to the 
innate immune system, particularly macrophages, as an important modulator of the 
development and progression of hypertension.14-18 Whether this also modulates target organ 
injury is less clearly defined. We therefore hypothesized that targeted deletion of the mouse 
myeloid ETB receptor would exaggerate hypertensive end-organ injury. In the current study 
we infused ANG II for 6 weeks and examined injury in the kidney, eye, heart and vasculature. 
Surprisingly, myeloid ETB receptor deficiency protected from end-organ injury. These effects 
partly reflected a reduction in BP but also involved a tuning of macrophages to an anti-
inflammatory phenotype. Thus, targeting the myeloid ET system may provide an attractive 
and novel therapeutic strategy in the context of hypertensive end-organ damage.  
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Results  
Myeloid ETB receptor deficiency protects from ANG II-mediated renal injury   
After 6 weeks of ANG II infusion, renal excretory function was no different between mice 
with a myeloid-specific disruption of the Ednrb gene (LysM-Cre Ednrblox/lox) and littermate 
controls (mice with no expression of Cre recombinase Ednrblox/lox) (Figure 1A). Ednrblox/lox 
mice developed progressive, heavy albuminuria over this period. By contrast, LysM-Cre 
Ednrblox/lox mice displayed only a modest rise in urinary albumin excretion which did not 
progress between week 3 and week 6 (at 6 weeks: 564±86 vs. 139±44 g/M, p <0.001, Figure 
1B). Consistently, there was less glomerulosclerosis at 6 weeks in LysM-Cre Ednrblox/lox mice 
compared to controls (61±4 vs. 34±2%, p <0.0001, Figures 1C & 1D). Additionally, there 
was a greater preservation of glomerular ultrastructure – less glomerular basement membrane 
thickening and podocyte foot process broadening and effacement – in LysM-Cre Ednrblox/lox 
mice compared to control mice (Figure 1E).  
 
The protective effects of the myeloid ETB receptor extended to ANG II-mediated tubular 
injury with LysM-Cre Ednrblox/lox mice demonstrating fewer tubular casts after 6 weeks of 
ANG II compared to Ednrblox/lox (Figures 1F & 1G). This was supported by lower cortical 
and medullary Kim-1 expression in knockout mice compared to controls at 6 weeks (Figure 
1H).  
 
Myeloid ETB receptor deficiency reduces ANG II-mediated renal inflammation 
At baseline, there was no difference in the number of renal resident macrophages between 
LysM-Cre Edrnblox/lox and Ednrblox/lox mice. Six weeks of ANG II increased the number of 
renal macrophages to a greater extent in Ednrblox/lox mice than in those deficient in myeloid 
ETB receptors (at 6 weeks, F4/80+ area/total area: 1.5±0.3 vs. 3.8±0.4%, p <0.001, Figure 
2A). Similarly, the number of renal T lymphocytes was no different between the two groups 
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at baseline and increased to a greater extent in Edrnblox/lox mice following 6 weeks of ANG II 
than in Lys M-Cre Edrnblox/lox mice (at 6 weeks, CD3+ area/total area: 3.2±0.6 vs. 6.9±1.1%, 
p <0.01, Figure 2B). 
 
Myeloid ETB receptor deficiency promotes an anti-inflammatory renal environment in 
response to ANG II 
We went on to further examine the effects of ANG II on the balance between a pro-
inflammatory (Tnfα and Il-6) and anti-inflammatory (Mrc1 and Arg1) environment within the 
kidney. At baseline, and in both cortex and medulla, Tnfα, Il-6, Mrc1 and Arg1 expression did 
not differ between LysM-Cre Edrnblox/lox and Edrnblox/lox mice (Figures 3A- 3D). Following 6 
weeks of ANG II, cortical and medullary Il-6 expression increased ~4-6-fold and medullary 
Tnfα ~3-fold in control mice whereas, LysM-Cre Ednrblox/lox mice displayed a modest increase 
in medullary Il-6 but no change in Tnfα in either compartment (Figures 3A & 3B). 
Conversely, whereas Edrnblox/lox mice demonstrated no changes in cortical or medullary Mrc1 
and Arg1 expression following ANG II, knockout mice upregulated cortical Arg1 and 
medullary Mrc1 (Figures 3C & 3D).   
  
Myeloid ETB receptor deficiency protects from ANG II-mediated retinal injury   
Prolonged uncontrolled hypertension leads to the development of retinal hemorrhages and 
immune cell infiltration. Deletion of the ETB receptor on myeloid cells alone significantly 
reduced the number of retinal hemorrhages seen following ANG II infusion by ~90% (Figure 
4A). Six weeks of ANG II led to vessel rarefaction in the inner retina plexus in Edrnblox/lox 
mice, whereas the vessel density of LysM-Cre Ednrblox/lox mice was preserved (Figure 4B). In 
addition, control mice demonstrated a greater number of activated microglia in the inner 
retina in response to 6 weeks of ANG II compared to knockout mice (Figure 4C). Activated 
microglia exhibited a typical round shape with larger cell body and short neurites.  
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Myeloid ETB receptor deficiency does not affect ANG II-mediated cardiac hypertrophy & 
dysfunction 
Six weeks of ANG II led to changes in cardiac structure that were in keeping with the 
development of left ventricular hypertrophy; these did not differ between LysM-Cre 
Edrnblox/lox and Edrnblox/lox mice (data not shown). ANG II infusion led to a similar increase in 
heart rate (Figure 5A) and reduction in cardiac output (CO) (Figure 5B) in both groups. 
LysM-Cre Ednrblox/lox and littermates also showed a similar reduction in left ventricular 
shortening fraction (Figure 5C).   
 
Myeloid ETB receptor deficiency protects from ANG II-mediated endothelial dysfunction   
As expected, 6 weeks of ANG II infusion reduced renal artery blood flow by ~50% and this 
fall was no different between LysM-Cre Edrnblox/lox and control mice (Figure 5D). ANG II 
did not affect basilar artery blood flow (Figure 5E) in either group. Interestingly, LysM-Cre 
Edrnblox/lox displayed greater basilar artery vascular reactivity at baseline compared to controls 
(20±1 vs. 11±2%, p <0.01). Following 6 weeks of ANG II, and in keeping with the 
development of significant vascular dysfunction, this response was abolished in Edrnblox/lox 
mice whereas LysM-Cre Edrnblox/lox mice retained a significant, albeit reduced, basilar artery 
vasodilatory capacity that remained within the physiological range (10±2 vs. 0±3%, p <0.05, 
Figure 5F). In keeping with these data, whereas there were no differences in the responses of 
isolated mesenteric vessels from knockout and control mice to acetylcholine (endothelium-
dependent) and sodium nitroprusside (endothelium-independent) vasodilation at baseline, 6 
weeks of ANG II led to impairment of both but with less marked effects in myeloid ETB 
receptor deficient mice compared to controls (Figure 6).  
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Myeloid ETB receptor deficiency has a biphasic effect on long-term ANG II-mediated 
hypertension & promotes natriuresis 
LysM-Cre Edrnblox/lox mice demonstrated an exaggerated BP response to ANG II during the 
first 2 weeks of infusion, confirming our previous work.13 Extending the protocol, we 
demonstrated that this exaggerated BP response was not sustained. Indeed, there was a 
reversal during weeks 3-4 such that in weeks 5 and 6, knockout mice now had a significantly 
lower BP compared to controls (Figure 7A).  
 
Next, we examined renal salt excretion at key time points over the course of the 6-week study. 
Before ANG II infusion, sodium excretion was no different between genotypes. Infusion of 
ANG II induced an increase in natriuresis in control mice and this was sustained through the 
6-week course of the study. The response was different in myeloid ETB receptor deficient 
mice: the early natriuresis was blunted (Figure 7B), concomitant with the exaggerated 
hypertensive response to ANG II; by week 6, the natriuresis was significantly greater than in 
controls, coincident with the reversal of BP.  ETB receptors are expressed in the principal cell 
of the renal tubule. Activation of ETB here inhibits the epithelial sodium channel (ENaC) to 
promote natriuresis. We therefore examined renal expression of the ETB receptor and αENaC 
subunit (the rate-limiting step for functional ENaC formation). Pre-ANGII, there was no 
difference between genotypes in the expression of either ETB or αENaC mRNA. At 6 weeks, 
control mice showed a significantly increased abundance of αENaC mRNA in both the cortex 
and medulla, which was not evident in LysM-Cre Edrnblox/lox mice. Notably, only LysM-Cre 
Edrnblox/lox mice showed a significant increase in ETB expression after 6 weeks of ANG II 
infusion (Figure 7C). 
 
Myeloid ETB receptor deficiency promotes an anti-inflammatory macrophage & neutrophil 
phenotype in response to ANG II 
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Next, we explored the effects of ANG II and myeloid ETB receptor deficiency on macrophage 
and neutrophil phenotype. At baseline, there were no differences seen between macrophages 
from Edrnblox/lox or LysM-Cre Edrnblox/lox mice in terms of their ability to polarize to an 
inflammatory (M1) or anti-inflammatory (M2) phenotype, or their phagocytic ability 
(Supplementary table 1). Interestingly, after 6 weeks of exposure to ANG II, macrophages 
harvested from LysM-Cre Edrnblox/lox mice demonstrated less of an M1 phenotype and more 
of an M2 phenotype than macrophages from littermate controls (Figures 8A-8C). Knockout 
macrophages also displayed a greater phagocytic capacity than controls at this timepoint 
(Figure 8D). Neutrophils from Edrnblox/lox or LysM-Cre Edrnblox/lox mice did not differ at 
baseline in terms of cytokine production. However, after exposure to 6 weeks of ANG II 
neutrophils from knockout mice were less inflammatory compared to control cells (Figures 
9A & 9B). 
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Discussion  
Damage to the kidney, heart, eye and arteries underpins the devastating consequences of 
sustained hypertension. In this study we purposefully used an extended-duration ANG II 
infusion to model such end-organ injury with stable hypertension. In the kidney, injury to 
both the glomerular and interstitial compartments was apparent and the gradual development 
of proteinuria and glomerulosclerosis is analogous to that observed in human progressive 
CKD. We examined how ET-1/ETB signaling in myeloid cells contributed to the development 
of organ injury. Our study had 3 main findings. First, we have demonstrated, for the first time, 
that activation of the myeloid ETB receptor makes a significant contribution to renal, retinal 
and vascular injury induced by ANG II. Second, the injurious role of myeloid cell ET-1/ETB 
signaling may reflect polarization of macrophages to a pro-inflammatory phenotype. Third, 
myeloid cell ETB receptors modulate the BP response to ANG II infusion in a biphasic way, a 
Janus-faced role of macrophages that is relevant to progressive human disease.  
  
Current research shows that macrophages play diverse roles in hypertension. Crowley et al 
showed that mice lacking ANG type 1 receptors on bone marrow derived cells develop 
exaggerated hypertension and proteinuria during ANG II infusion16 whilst Rickard et al 
studied mice with a macrophage-specific knockout of the mineralocorticoid receptor and 
found they were protected from deoxycorticosterone acetate (DOCA)/salt induced 
hypertension.17 As opposed to altering macrophage phenotype, Wenzel and colleagues 
elegantly depleted macrophages and found that this markedly blunted virtually all 
consequences of chronic ANG II infusion, including BP elevation, superoxide production, 
vascular dysfunction and fibrosis (some of these effects may have been due to modulation of 
the ET system).15 We also found that macrophages provide a buffering mechanism in the 
development of hypertension. The presence of a functional ET-1/ETB signalling cascade in 
macrophages slowed the initial rise in BP induced by a 2-week infusion of either ET-1 or 
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ANG II.13 The hypertension induced by ANG II is partly mediated by ET-1 and we found in 
both models that the initial BP-lowering effect of macrophages reflected clearance of ET-1, 
dependent on an unblocked ETB receptor and intact endocytosis.13 We now show that this 
‘protective’ role of ET-1/ETB in macrophages is not sustained. The BP differential between 
mice with and without macrophage ETB receptors is lost beyond two weeks, and indeed 
reverses after 4 weeks of ANG II treatment. An ‘injurious’ role for macrophage ETB 
ultimately emerges such that specific deletion of this receptor substantially reduces organ 
injury in the kidney, eye and vasculature, at least in the setting of ANG II hypertension. This 
remains to be confirmed in an ET-1 infusion model. Similarly, we have not yet explored 
whether the myeloid ETA receptor, expressed at much lower levels that the ETB receptor,13 
contributes to injury progression. 
 
By extending our examination of ANG II hypertension beyond two weeks, we highlight 
diverse and changing roles for macrophages in BP regulation. The hypertensive reversal after 
3-4 weeks was associated with marked improvement in the natriuretic response. Our data 
point to a mechanism involving increased tubular ET-1/ETB signalling and down-regulation 
of ENaC mediated sodium re-absorption in the distal nephron. Moreover, the magnutide of 
the natriuresis is large and it is likely that transporters in other segments of the nephron are 
downregulated. Defining how the nephron functionally remodels sodium transport could be 
assessed by examining the natriuretic response to a panel of diuretics19 and is a future 
direction of our research. Similarly, how deletion of myeloid cell ETB receptor leads to 
upregulation of the same system in the principal cell is currently unclear. Recent studies show 
that renal epithelial cells produce chemokines to orchestrate intrarenal distribution of 
monocyte-derived cells.20,21  Whether our data uncover direct ‘myeleo-tubular’ crosstalk 
within the normal operation of the ET-1 pathway requires further investigation.  
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Chronic ANG II infusion also promotes renal T-cell and macrophage infiltration, shown here 
and by others.22,23 This infiltration was substantially reduced by myeloid ETB deficiency, 
which also shifted the renal cortico-medullary environment from an inflammatory to a more 
anti-inflammatory one. Together these suggest that the macrophage ET-1/ETB signalling 
system operates to promote inflammation and injury in the long-term. Certainly, sustained 
ANG II treatment upregulates the vascular and renal ET system.6,7 We have previously shown 
that macrophages display ETB-dependent chemokinesis towards ET-1. It is plausible that the 
increase in renal macrophages seen after 6 weeks of ANG II infusion reflects recruitment of 
monocytes to the kidney in chemokinetic response to a high systemic-intrarenal ET gradient. 
Moreover, effective ETB blockade disrupts the myeloid ETB sensing mechanism, leading to 
fewer circulating monocytes transitioning to the kidneys. Others have explored renal 
inflammation and the contribution that the ET system makes to this. Boesen et al. showed that 
during a 2-week infusion of ANG II in mice, ETA receptor activation mediated a BP-
independent increase in renal cortical T-cells whereas medullary T-cell and cortico-medullary 
macrophage infiltration was BP-dependent.24 Similarly, in a model of diabetic nephropathy, 
treatment with an ETA antagonist reduced renal macrophage infiltration and fibrosis.25 In both 
studies ET receptor blockade was given systemically and so the specific cell mediating the 
beneficial effects was unclear.  
 
Although no different at baseline, macrophages from myeloid ETB knockout mice taken after 
six weeks of exposure to ANG II displayed a more M2/anti-inflammatory and reparative 
phenotype than those from littermate control mice which showed a more M1/inflammatory 
one. The ability of ANG II to promote an inflammatory macrophage phenotype is well 
recognized.26-28 However, its exact mechanism remains unclear. Our data suggest an 
interaction between macrophage ANG II receptors and ETB to promote this phenotypic 
switch. ANG II-mediated hypertension and end-organ injury are to a large extent mediated by 
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an upregulation of the ET system. Thus, ET receptor antagonism is able to abrogate these 
effects.6,7 However, previous studies have not explored the type and location of the ET 
receptor involved. Our novel findings support a key role for macrophage ETB receptors in 
mediating these effects. 
 
Few recent studies have explored the effects of ANG II-mediated hypertension on the eye. 
Retinal hemorrhages and vascular loss are characteristic of hypertensive eye injury and both 
were seen here. They were reduced with myeloid ETB deficiency as was retinal inflammation 
assessed by microglial activation. ANG II contributes to a number of eye disorders including 
diabetic retinopathy, glaucoma and retinopathy of prematurity.29 In retinopathy of 
prematurity, blockade of ANG type 1 receptors promotes the re-establishment of normal 
vessel growth and reduces microglia recruitment.30 These effects are similar to those seen 
here and so targeting the myeloid ET system may provide a novel direction for future studies 
in these areas. Indeed, one study in diabetic mice showed an improvement in the retinal 
vascular network and reduced pericyte loss with the ETA antagonist, atrasentan.31  
 
As expected, chronic ANG II infusion resulted in both endothelium-dependent and 
endothelium-independent dysfunction. This injury is a result of damage to both the vascular 
endothelial cell and underlying smooth muscle cell. This was ameliorated by myeloid ETB 
receptor deficiency. The mechanisms for this protection probably relate in part to the shift in 
macrophage phenotype we observed in response to ANG II between the two groups of mice. 
It is well recognized that inflammatory macrophages contribute to endothelial 
dysfunction.15,32 Phagocytosis also contributes to inflammation resolution through removal of 
cell debris.33 Here, phagocytic capacity of knockout macrophages was greater than in controls 
and so this may also explain the differential effects seen in the kidneys, eye and vasculature. 
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In the current study, the magnitude of the anti-proteinuric and anti-fibrotic effects of effective 
myeloid ETB receptor blockade (~40-60%) is similar to that seen with ET receptor 
antagonists. As both selective ETA and mixed ETA/B receptor antagonists are available in the 
clinic the addition of our own data to these earlier studies suggest that both approaches may 
be beneficial in reducing ANG II-mediated renal damage which is the one of the main 
mechanisms in the development and progression of CKD. Consistent with this, the recent 
SONAR study demonstrated the efficacy of atrasentan, an endothelin-A antagonist, in 
slowing diabetic CKD progression when added to renin-angiotensin system blockade.8  
 
In summary, our study has identified a novel role for the myeloid ET system in mediating 
ANG II-associated injury in the eye, kidney and vasculature. The long-term protective effects 
of deleting the myeloid ETB receptor were only resolved by extending the duration of our 
experiment, highlighting the importance of 'time' as a factor when modeling chronic, 
progressive human disorders. The protection ultimately conferred by myeloid ETB receptor 
depletion may be partly hemodynamic, reflecting the lowering of BP following natriuresis. 
Our data also indicate that reprogramming of macrophage and/or neutrophil phenotype and 
function is likely to be important. We cannot currently discriminate the relative contributions 
of macrophages and neutrophils to this protective phenotype, a limitation of the study 
requiring further work. Moreover, we cannot yet clearly map across to humans the biphasic 
BP response to myeloid ETB receptor deletion. We previously reported that 
cyclophosphamide therapy, depleting circulating monocytes and tissue macrophages (as well 
as T- and B-cells), increased BP in patients with vasculitis,13 at least initially and a longer 
study is now needed. This is relevant, since targeting the immune system is recognized as an 
effective treatment for hypertension in man as seen in studies using IL6 antagonism34 and 
immunisation against ANG II.35 Similarly, macrophage cell therapy is currently being 
explored as an anti-inflammatory approach in a number of disease states.36-38 Combining 
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these with newer monoclonal antibodies that specifically target ETA and ETB39 might allow 
the current data to be explored in the clinical setting. 
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Methods (please also see Supplemental material) 
Angiotensin II (ANG II)-mediated end-organ damage 
Mice were infused ANG II (1µg/kg/min, SigmaAldrich) subcutaneously using osmotic mini 
pumps (Alzet, model 2006) for a period of six weeks. Animals were fed a high-salt diet (NaCl 
3%) and had free access to food and water. BP was measured in conscious, unrestrained mice 
using a radio-telemetry system (PA-C10 and Dataquest software, Data Sciences 
International). Recordings were obtained every 15min for 60s; daytime was defined as 0700 -
1900 and nighttime as 1900 - 0700.  
 
Assessment of renal function and albuminuria  
Blood urea nitrogen (BUN) and urinary creatinine concentrations were quantified 
spectrophotometrically by colorimetric methods. Urinary albumin was measured with a 
specific ELISA assay (Cusabio, CSB-E13878m).  
 
Renal histopathology and immunohistochemistry  
Kidneys were immersed in 10% formalin and embedded in paraffin. 4mm sections were 
processed for histopathology or immunohistochemistry. Glomerulosclerosis was defined by 
focal and segmental consolidation of the tuft by increased extracellular matrix, obliterating 
the glomerular capillary lumen. For assessment of glomerulosclerosis, an examiner blinded to 
the experimental conditions assessed the % of glomeruli showing glomerulosclerosis with at 
least 50 glomeruli examined per field. For immunohistochemistry, paraffin embedded 
sections were stained with the following primary antibodies: rabbit anti-CD3 (DAKO, A 
0452, 1:200), rat anti-F4/80 (AbDSerotec, MCA497, 1:500). CD3 and F4/80 staining were 
exposed with Histofine reagent (Nichirei Biosciences, 414141F) and color formation stopped 
by washing in PBS. Slides were then counterstained with hematoxylin. Photomicrographs 
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were taken with an Axiophot Zeiss photomicroscope (Jena, Germany). Quantification of CD3 
and F480 staining was performed using ImageJ software.   
Electron microscopy: Sections of renal cortex were fixed in Trump’s solution (EMS, 11750) 
and embedded in Araldite M (Sigma Aldrich, 10951). Ultrathin sections were counter-stained 
with uranyl acetate and lead citrate and examined with a transmission electron microscope 
(JEM, JEOL 1011, Peabody, MA, USA). 
 
Assessment of retinal injury  
After enucleation, eyes were fixed in 4% paraformaldehyde for 30min at room temperature. 
After washing in PBS, and removal of the cornea and lens, the retina was dissected from the 
retinal pigment epithelium/choroid/sclera. Retinas were incubated overnight with primary 
antibodies (lectin Alexa conjugated, 1:100, Invitrogen; rabbit anti-Iba1, 1:400, Wako, USA) 
in PBS supplemented with 0.5% Triton X-100, followed by incubation with appropriate 
Alexa-coupled secondary antibodies (Life Technologies). Retinas were flat-mounted and 
viewed with a fluorescence microscope (DM5500B, Leica, France). Vascular network and 
activated Iba1+ cell density were calculated from an average of 8 images/animal (4/retina). 
Vascular network density was obtained using NeuronJ plugin on ImageJ software. 
 
Non-invasive ultrasound assessment of cardiac, renal and cerebral hemodynamics  
Ultrasound examination was carried out under isoflurane anesthesia using an echocardiograph 
(Acuson S3000; Siemens®, Erlangen, Germany) equipped with a 14MHz linear transducer 
(14L5 SP). Mice were placed on a heating blanket (38°C) to avoid hypothermia.  
Cardiac parameters and cardiac output (CO): A parasternal long-axis B-mode image was 
used to measure CO using the mean of three successive measurements. Heart dimensions 
measured, in both systole and diastole, included left ventricular posterior wall thickness, left 
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ventricular internal diameter, and inter-ventricular septum thickness. Heart rates were 
obtained with an electrocardiogram.  
Renal artery blood flow velocity (BFV): A pulsed Doppler sample gate was placed on the 
longitudinal axis of the right renal artery and the pulsed Doppler spectrum was recorded. 
Time-averaged mean BFV was calculated with correction of the angle between the long axis 
of each vessel and the Doppler beam.   
Cerebral vasoreactivity: A horizontal B-mode image at the skull base allowed imaging of the 
basilar trunk and both internal carotid arteries. Color Doppler mode was activated and the 
basilar trunk with the circle of Willis were drawn and localized on the screen by their color-
coded blood flow. A pulsed Doppler sample gate was placed on the longitudinal axis of the 
basilar trunk and the pulsed Doppler spectrum was recorded by a masked operator. 
Vasoreactivity was quantified as the percentage increase in mean blood flow velocity (mBFV) 
after 5min inhalation of 16% O2/5% CO2/79% N2 compared to mBFV on ambient air.40  
  
Ex vivo myography 
This is described in detail elsewhere.41 In brief, 2mm segments of aorta and second order 
mesenteric arteries were mounted in a multi-myography system (610M, Danish Myo 
Technology, Denmark) containing physiological salt solution aerated at 37oC with 95% 
O2/5% CO2. In all studies vessel viability was first confirmed by a contractile response on 
addition of 80mM KCl, repeated three times. Vessel contractility was then assessed by 
cumulative concentration-response curves to phenylephrine (PE; 1nM-3μM), noradrenalin 
(1nM-3μM) and ET-1 (1pM-30nM) and we selected a concentration that produced 80% 
maximum contraction for each individual vascular ring. To assess vasodilator capacity, 
vessels were pre-constricted with PE and cumulative concentration curves were obtained to 
acetylcholine (1nM-3μM) and sodium nitroprusside (1nM-3μM). At least 30min washout was 
allowed between drugs. Results are presented as percentage of a maximal response. 
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In vitro culture of peritoneal macrophages & bone marrow derived neutrophils 
Freshly isolated peritoneal macrophages were plated in 6-well plates at a density of 5x105 
cells/3.8cm2 in RPMI 1640 culture medium supplemented with 10% fetal calf serum and 1% 
penicillin/streptomycin (Life Technologies, 15140–122) and left to adhere for 24h. Cells were 
then incubated with LPS/INFγ (100ng/ml/10ng/ml, Sigma-Aldrich) or IL4/IL13 (10ng/ml for 
both, Invitrogen) for 24h. Bone marrow derived neutrophils were isolated and cultured in 
vitro as previously described.42 Cells were then incubated with LPS (100ng/ml, Sigma-
Aldrich) for 24h. 
 
Cell culture supernatants were removed and frozen immediately at -80°C until analysis. IL1β, 
IL6 and TNFα were determined using ELISA (R&D Systems) according to the 
manufacturer’s instructions. Samples were analysed in duplicate at 450nm with wavelength 
correction at 570nm (Synergy HT BioTEK). Concentrations were calculated from a standard 
curve using a second order (quadratic) regression analysis. To assess phagocytic ability, 
macrophages were incubated with fluorescent beads (10:1 ratio) for 60 min. Cells were 
vigorously washed and detached from the plates prior to quantification of phagocytosis by 
flow cytometry. 
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Figure legends  
Figure 1: Specific deletion of Ednrb from myeloid cells protects from ANG II-mediated 
renal injury  
(A) Blood urea nitrogen concentration at 6 weeks, (B) urinary albumin excretion and (C) 
glomerulosclerosis at 6 weeks in Ednrblox/lox and LysM-Cre Ednrblox/lox mice following ANG 
II. (D) Representative images of Masson’s trichrome-stained kidney cortex from Ednrblox/lox 
and LysM-Cre Ednrblox/lox mice after 6 weeks of ANG II. (E) Representative transmission 
electron micrographs of glomeruli from Ednrblox/lox and LysM-Cre Ednrblox/lox at 6 weeks.  
The * highlights an area of podocyte foot process effacement and fusion in Ednrblox/lox mice 
and an area of normal podocyte ultrastructure in LysM-Cre Ednrblox/lox mice. (F) 
Representative images of Masson’s trichrome-stained kidney medulla from Ednrblox/lox and 
LysM-Cre Ednrblox/lox mice after 6 weeks of ANG II with (G) associated quantification of 
tubular casts. (H) RT-qPCR analysis of cortical and medullary Kim-1 message at baseline and 
after 6 weeks. Data represent mean ± SEM of n=10 mice/group. *p <0.05, ***p <0.001 and 
****p <0.0001 for baseline compared to week 6 within the same genotype; $p <0.05 and ψp 
<0.001 for one genotype compared to the other at the same time point. Between group 
comparisons for normally distributed data were by t-test (C, G) or two-way ANOVA with 
Sidak post-test of plan comparisons (B, H). For between group comparisons of non-normally 
distributed variables, a Mann-Whitney test (C) or Kruskal-Wallis test was employed. Scale 
bar: 20µm. 
 
Figure 2: Specific deletion of Ednrb from myeloid cells reduces ANG II-mediated renal 
inflammation 
Representative images of renal (A) F4/80 and (B) CD3 staining on kidney sections from 
Ednrblox/lox and LysM-Cre Ednrblox/lox mice at baseline and after 6 weeks of ANG II infusion. 
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Data represent mean ± SEM of n=8 mice/group. **p<0.01 for one genotype compared to the 
other. Between group comparisons were made by un-paired t-test. Scale bar: 20µm. 
 
Figure 3: Specific deletion of Ednrb from myeloid cells promotes an anti-inflammatory 
renal environment in response to ANG II 
RT-qPCR analysis of renal cortex and medulla of Ednrblox/lox and LysM-Cre Ednrblox/lox mice 
before and after 6 weeks of ANG II. Data represent mean ± SEM fold change from baseline; 
n=7 mice/group. *p <0.05 for baseline compared to week 6 within the same genotype; $p 
<0.05 for one genotype compared to the other at the same time point. Comparisons were 
made by two-way ANOVA with Sidak post test for planned comparisons.  
 
Figure 4: Specific deletion of Ednrb from myeloid cells protects from ANG II-mediated 
retinal injury  
All data are following 6 weeks of ANG II. (A) Quantification of retinal hemorrhagic spots 
in Ednrblox/lox and LysM-Cre Ednrblox/lox mice. (B) Representative images of inner retina 
vascular network stained with lectin from Ednrblox/lox and LysM-Cre Ednrblox/lox mice. 
Vascular network density was calculated from an average of 4 images/retina using the 
NeuronJ plugin on ImageJ software. (C) Representative images of microglia within the inner 
retina stained with iba-1 antibody from Ednrblox/lox and LysM-Cre Ednrblox/lox mice. Activated 
microglia, which have an amoeboid morphology with a large cell body and short neurites (*), 
were counted from 4 images/retina. Data represent mean ± SEM; n=5 mice per group. *p 
<0.05 and **p<0.01 for one genotype compared to the other. Between group comparisons 
were performed with a Mann-Whitney test. Scale bar: 50µm 
 
Figure 5: Specific deletion of Ednrb from myeloid cells does not affect ANG II-mediated 
cardiac injury 
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Effects on (A) heart rate, (B) cardiac output, (C) fractional shortening, (D) renal artery blood 
flow, (E) basilar artery blood flow and (F) basilar artery vascular function at baseline and 
following 6 weeks of ANG II in Ednrblox/lox and LysM-Cre Ednrblox/lox mice. Data represent 
mean ± SEM of n=8 mice/group. *p <0.05, **p <0.01; ***p <0.001 for baseline compared to 
week 6 within the same genotype; $p <0.05 for one genotype compared to the other at the 
same time point. Comparisons were made by two-way ANOVA with Sidak post test for 
planned comparisons. 
 
Figure 6: Specific deletion of Ednrb from myeloid cells protects from ANG II-mediated 
endothelial dysfunction   
Endothelium-dependent (acetylcholine) and endothelium-independent (sodium nitroprusside) 
vascular function in Ednrblox/lox and LysM-Cre Ednrblox/lox mice at baseline and following 6 
weeks of ANG II. Data represent mean ± SEM of n=8 mice/group. Between group 
comparisons were performed with a two-way ANOVA. 
 
Figure 7: Specific deletion of Ednrb from myeloid cells has a biphasic effect on the BP 
response to ANG II and promotes long-term natriuresis 
(A) Systolic and diastolic BP of Ednrblox/lox and LysM-Cre Ednrblox/lox mice during 6 weeks of 
ANG II infusion. (B) urinary sodium excretion over this 6-week period. (C) Expression of 
cortical and medullary αENaC and ETB receptor in Ednrblox/lox and LysM-Cre Ednrblox/lox 
mice at baseline and following 6 weeks of ANG II. Data represent mean ± SEM of n=5-7 
mice/group. *p <0.05 and ***p <0.001 for baseline compared to week 6 within the same 
genotype; $p <0.05 for one genotype compared to the other at the same time point. Between 
group comparisons were performed with two-way ANOVA. 
 
Figure 8: Specific deletion of Ednrb from myeloid cells promotes an anti-inflammatory 
macrophage phenotype in response to ANG II 
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Peritoneal macrophages were harvested from Ednrblox/lox and LysM-Cre Ednrblox/lox mice after 
6 weeks of ANG II. (A) a range of M1 macrophage markers and (B) cytokines were assessed 
following stimulation with LPS/INFγ; (C) M2 markers were assessed following stimulation 
with IL4/IL13; (D) phagocytosis. Data are mean ± SEM; n=6/group. *p <0.05, **p <0.01 and 
***p < 0.001 for one genotype compared to the other. Between group comparisons were 
perfomed with a one-way ANOVA with Sidak post test for planned comparisons.. 
 
Figure 9: Specific deletion of Ednrb from myeloid cells promotes a less inflammatory 
neutrophil phenotype in response to ANG II 
Bone marrow derived neutrophils from Ednrblox/lox and LysM-Cre Ednrblox/lox mice were 
cultured in vitro after 6 weeks of ANG II. (A) TNFα and (B) IL6 production following 
stimulation with LPS. Data are mean ± SEM; n=5/group. *p <0.05 for baseline compared to 
week 6 within the same genotype; $p <0.05 for one genotype compared to the other at the 
same time point. Comparisons were made by two-way ANOVA with Sidak post test for 
planned comparisons.  









